Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Everolimus Stories

2013-05-20 23:19:09

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

2013-05-17 04:20:42

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER((TM)) Stent...

2013-03-14 12:27:36

CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Cyberonics Inc. (Nasdaq:CYBX), Given Imaging. (Nasdaq:GIVN) and Aflac Inc. (NYSE:AFL). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the...

2013-03-11 12:24:19

-- Three-year clinical results for treating clogged vessels in the heart with Absorb presented at American College of Cardiology 2013 SAN FRANCISCO, March 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb(TM) Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session of the American College of...

2013-03-10 12:20:23

Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent NATICK, Mass., March 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System to the Cobalt Chromium (CoCr) Xience V® Everolimus-Eluting Coronary...

2013-02-15 20:21:09

EAST HANOVER, N.J., Feb. 15, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress(®) (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant. Zortress is the first mammalian target of rapamycin (mTOR) inhibitor approved for use following liver transplantation. It is also the first immunosuppressant approved by the FDA in over a decade for use following liver transplantation.(1 )...

2013-02-12 08:31:56

NATICK, Mass., Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch. The Promus PREMIER Stent System is designed to provide physicians improved DES performance in treating patients with coronary artery disease. It is the only...

2013-01-11 13:23:29

Study shows drug can shrink tumors and save kidneys Thousands of individuals have had kidneys removed unnecessarily because doctors misdiagnosed their disease. A new, international study published in The Lancet indicates that approximately one of every five individuals with kidney tumors common in patients with tuberous sclerosis complex (TSC), a genetic disorder, has had a kidney removed. Moreover, 40 percent had some kind of surgical procedure performed. Proper diagnosis could have...

2013-01-10 20:21:54

EAST HANOVER, N.J., Jan. 10, 2013 /PRNewswire/ -- Data published today in The Lancet showed that patients on Afinitor(®) (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression(1). Additionally, a recent issue of The Lancet featured results from a separate everolimus trial demonstrating a reduction in the size of non-cancerous...

2013-01-08 08:30:42

ABBOTT PARK, Ill., Jan. 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United States, and compare the performance of Abbott's drug eluting Absorb((TM)) Bioresorbable Vascular Scaffold (BVS) device to the company's XIENCE((TM)) family of drug eluting stents. The start of this trial in the United...